Illumina, Inc. (ILMN) · Oct 29, 2026 · Earnings
Beat — Ex-refund non-GAAP EPS $1.44 vs ~$1.36 consensus; ex-refund revenue $1.166B vs ~$1.15B consensus
Illumina’s Q3 earnings beat on underlying EPS and revenue, with clinical demand and NovaSeq X placements driving another full-year guidance raise.
Illumina is in the middle of a recovery-and-reacceleration plan: moving beyond weak research and China demand toward clinical sequencing, broader NovaSeq X adoption, and better operating leverage. Earlier 2026 results already showed NovaSeq X-led instrument and consumables demand supporting growth, while tariffs and China remained meaningful headwinds.
The quarter beat the market underneath a distorted revenue headline. Reported revenue of $1.129 billion was below the published consensus of roughly $1.15 billion, but the comparison is skewed by $37 million of tariff refunds expected to be credited back to customers. Excluding that refund, revenue was $1.166 billion, modestly above consensus, while non-GAAP EPS excluding tariff refunds was $1.44 versus roughly $1.36 expected. The clean read is an underlying beat, not a reported-line miss.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Financial Highlights) | $1,129M | $1,084M | ~$1,150M |
| Revenue excluding tariff refunds (Financial Highlights) | $1,166M | ~$1,150M | |
| Non-GAAP diluted EPS (EPS reconciliation) | $1.62 | $1.34 | ~$1.36 |
| Non-GAAP EPS excluding tariff refunds (EPS reconciliation) | $1.44 | $1.34 | ~$1.36 |
| ROW organic revenue growth (Revenue growth reconciliation) | 4.7% | ||
| Free cash flow (Cash Flow statement) | $378M | $253M |
Clinical demand is becoming the more important proof point. Management specifically attributed the quarter to healthy clinical demand and robust NovaSeq X placements, suggesting the growth strategy is gaining traction in the higher-value clinical market rather than relying only on a temporary accounting benefit. The business still grew only 4.7% on a ROW organic basis, so this is progress, not a wholesale acceleration. 〔0〕
Margins and cash generation materially strengthened. Non-GAAP operating margin excluding tariff refunds rose to 25.0% from 24.5% a year earlier, while free cash flow increased to $378 million from $253 million. That matters because Illumina’s strategic reset depends not just on returning to growth, but on converting the recovery into durable profitability and cash.
The outlook moved in the right direction again. Illumina raised full-year revenue and earnings guidance after already increasing its outlook in the prior quarter, making the guidance action more meaningful than a first-time reset. The filing does not provide the new numerical ranges, so the size of the increase cannot be assessed here. 〔1〕
The main caveat is the quality of the EPS boost, not the direction of the quarter. Tariff refunds contributed $0.18 to non-GAAP EPS and $41 million to non-GAAP gross profit, so headline profitability overstates the recurring improvement. Even after removing that benefit, however, underlying EPS, revenue, margins, and cash flow all improved versus consensus or the prior year.
Bottom line: This is a genuine underlying beat and another step forward in Illumina’s clinical/NovaSeq X recovery story. The tariff refund muddies the headline numbers, but it does not erase the stronger operating performance or the raised outlook.
Q4 earnings and FY 2027 outlook
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!